Paper38803167
Metabolic Modulation-Mediated Antibiotic and Immune Activation for Treatment of Chronic Lung Infections.
Xiu W and 11 others. ACS Nano, 2024. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Metabolic Modulation-Mediated Antibiotic and Immune Activation for Treatment of Chronic Lung Infections. Papers, record 38803167. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38803167
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metabolic Modulation-Mediated Antibiotic and Immune Activation for Treatment of Chronic Lung Infections.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Pseudomonas aeruginosa | Major topic |
| Biofilms | Major topic |
| Pseudomonas Infections | Major topic |
| Animals | |
| Mice | |
| Nanoparticles | |
| Liposomes | |
| Chronic Disease | |
| Reactive Oxygen Species | |
| Prodrugs |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42703409 | Combating Bacterial Infection with Metabolism-Regulating Nanomaterials. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42703409 | PubMed |
| 42376009 | Amplifying bacterial cuproptosis by NIR driven biomimetic metal organic framework for nanocatalytic enhanced bacterial pneumonia immunotherapy. | Bioact Mater | 2026 | https://conductscience.org/library/papers/42376009 | PubMed |
| 42326064 | Bacterial phospholipid selective quaternary phosphonium polymers with potent antibacterial activity. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42326064 | PubMed |
| 41599183 | Charge Effects: Influence of Surface Charge on Protein Corona Adsorption Behavior on Liposomal Formulations. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41599183 | PubMed |
| 40821672 | Research progress of nano-based drug delivery systems based on stimuli-responsive materials for the treatment of lung diseases. | Front Bioeng Biotechnol | 2025 | https://conductscience.org/library/papers/40821672 | PubMed |
| 40427581 | The Effect of Microbiome-Derived Metabolites in Inflammation-Related Cancer Prevention and Treatment. | Biomolecules | 2025 | https://conductscience.org/library/papers/40427581 | PubMed |
| 39462395 | Multi-drug resistant Pseudomonas aeruginosa isolation is an independent risk factor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a retrospective cohort study. | Respir Res | 2024 | https://conductscience.org/library/papers/39462395 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38803167
GET https://conductscience.org/api/papers/v1/38803167/authors